Girl Dies as Pluristem Sells on Gains With Miracle Cells

Pluristem Therapeutics Inc.’s stock doubled in Nasdaq trading from May through September, helped by three news releases announcing that patients’ lives had been saved by injections of the company’s experimental stem cells.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.